Latozinemab (AL001) Emerging Drug Insight and Market Forecast - 2032

“Latozinemab (AL001) Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Latozinemab (AL001) for Frontotemporal dementia (FTD) in the 7MM. A detailed picture of the Latozinemab (AL001) for Frontotemporal dementia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Latozinemab (AL001) for Frontotemporal dementia. The report provides insight about mechanism of action, dosage, and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Latozinemab (AL001) market forecast, analysis for Frontotemporal dementia in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Frontotemporal dementia.

Drug Summary

Latozinemab (AL001) is Alector's wholly-owned humanized recombinant monoclonal antibody designed to modulate progranulin - a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer's disease, and Parkinson's disease. It aims to increase the progranulin level in humans by inhibiting the progranulin degradation mechanism. AL001 is being developed in collaboration with GSK.

Latozinemab, which is administered via intravenous peripheral infusion, works by inhibiting the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of functional PGRN in the brain. It is being developed to treat FTD patients who have a heterozygous loss-of-function mutation in granulin (FTD-GRN). Latozinemab was initially intended for FTD-GRN patients, but the company has now begun a Phase II clinical trial for FTD-C9orf72 patients, as well as several other neurological indications such as Alzheimer's and Parkinson's disease.

FTD-C9orf72 is associated with abnormal accumulation of the protein TDP-43. The Phase II study, which includes participants with progranulin mutations (FTD-GRN), is intended to assess the safety and tolerability of chronic AL001 dosing. Treatment with latozinemab was estimated to slow disease progression by 48% in 12 patients at 12 months.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Latozinemab (AL001) description, mechanism of action, dosage and administration, research and development activities in Frontotemporal dementia.
• Elaborated details on Latozinemab (AL001) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Latozinemab (AL001) research and development activity in Frontotemporal dementia in detail across the United States, Europe and Japan.
• The report also covers the patent's information with an expiry timeline around Latozinemab (AL001).
• The report contains forecasted sales of Latozinemab (AL001) for Frontotemporal dementia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Frontotemporal dementia.
• The report also features the SWOT analysis with analyst views for Latozinemab (AL001) in Frontotemporal dementia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research, and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

Latozinemab (AL001) Analytical Perspective

In-depth Latozinemab (AL001) Market Assessment

This report provides a detailed market assessment of Latozinemab (AL001) in Frontotemporal dementia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

Latozinemab (AL001) Clinical Assessment

The report provides the clinical trials information of Latozinemab (AL001) in Frontotemporal dementia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Frontotemporal dementia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Latozinemab (AL001) dominance.
• Other emerging products for Frontotemporal dementia are expected to give tough market competition to Latozinemab (AL001) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Latozinemab (AL001) in Frontotemporal dementia.
• This in-depth analysis of the forecasted sales data from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Latozinemab (AL001) in Frontotemporal dementia.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Latozinemab (AL001)?
• What is the clinical trial status of the study related to Latozinemab (AL001) in Frontotemporal dementia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Latozinemab (AL001) development?
• What are the key designations that have been granted to Latozinemab (AL001) for Frontotemporal dementia?
• What is the forecasted market scenario of Latozinemab (AL001) for Frontotemporal dementia?
• What are the forecasted sales of Latozinemab (AL001) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Frontotemporal dementia and how are they giving competition to Latozinemab (AL001) for Frontotemporal dementia?
• Which are the late-stage emerging therapies under development for the treatment of Frontotemporal dementia?

This product will be delivered within 2 business days.